2026 Participants
Verify your technical or digital innovation in an industrial biomanufacturing innovation challenge!
2026 Participants
We are delighted to announce the five companies selected for this year’s Testa Challenge.
The chosen participants are Holtra, Apriko, Nanospacer, QBDC and VentriLabs.
These innovative companies will join the Testa Challenge 2026, where they will have the unique opportunity to test their digital and technical solutions in a real biomanufacturing environment.
We are excited to see the innovative solutions these companies will bring to the Testa Challenge 2026 and look forward to the valuable insights and advancements that will emerge from this year’s challenge.
Here is some information about this year’s chosen companies:
Holtra Holographic particle tracking enables the identification of different particle types in liquids based on their density and structure. By tracking individual particles and determining their optical properties and movement, particle dispersions can be characterized in unprecedented detail. The primary focus is on life science applications, including nanomedicine and biopharma. Both instruments and analytical services are offered.
APRIKO develops AI-driven bioprocess intelligence solutions for biopharmaceutical manufacturing, helping teams predict key process outcomes, understand production variability, and support smarter decisions in process development, scale-up, and manufacturing.
Nanospacer AS provides NTA services for single molecule metrology, as well as sizing and quantification of EVs/Nanoparticles/Nanobubbles/Viruses/Amyloids/Oligomers/DNA/RNA in solution; The company provides consulting in mode-of-action studies for pharmaceutical drug screening (e.g. Alzheimer's & Parkinson disease drug discovery, Neurodegeneration) of molecular compounds using nanofluidic technology. R&D focus on next generation point-of-care diagnostics and scalable health data acquisition using AI & mass producible nano-, and microfluidic confinements.
QBDC GmbH is a biotech company developing EDDI, a platform that uses DNA methylation and AI to read cells’ “epigenetic memory” and understand how they respond to different conditions over time. Their main product, CellSense, applies this technology to bioprocessing, combining biological data and AI to predict cell behavior, improve process performance, and detect issues early. It helps pharmaceutical companies move from reactive troubleshooting to predictive control, enabling better decision-making, more stable processes, and more efficient drug production.
VentriLabs is a Swedish company developing advanced fluid handling solutions for bioprocessing. Its key product, the DuaFLO™ BioPump, provides smooth, low-shear, non-pulsatile flow to safely handle sensitive biological materials. The technology ensures precise flow control, reduces cell stress, and improves performance in both upstream and downstream processes, ultimately supporting higher yields and reliable large-scale production.
